Top

BMC Complementary Medicine and Therapies

Published in:

Open Access 01-12-2020 | Research article

Mechanisms of Spica Prunellae against thyroid-associated Ophthalmopathy based on network pharmacology and molecular docking

Authors: Yuhan Zhang, Xianzhi Li, Congcong Guo, Jianjun Dong, Lin Liao

Published in: BMC Complementary Medicine and Therapies | Issue 1/2020

Abstract

Background

Thyroid-associated ophthalmopathy (TAO) is an autoimmune inflammatory disorder, which lacks effective treatment currently. Spica Prunellae (SP) is popularly used for its anti-inflammatory and immune-regulating properties, indicating SP may have potential therapeutic value in TAO. Therefore, the purpose of this study is to identify the efficiency and potential mechanism of SP in treating TAO.

Methods

A network pharmacology integrated molecular docking strategy was used to predict the underlying molecular mechanism of treating TAO. Firstly, the active compounds of SP were obtained from TCMSP database and literature research. Then we collected the putative targets of SP and TAO based on multi-sources databases to generate networks. Network topology analysis, GO and KEGG pathway enrichment analysis were performed to screen the key targets and mechanism. Furthermore, molecular docking simulation provided an assessment tool for verifying drug and target binding.

Results

Our results showed that 8 targets (PTGS2, MAPK3, AKT1, TNF, MAPK1, CASP3, IL6, MMP9) were recognized as key therapeutic targets with excellent binding affinity after network analysis and molecular docking-based virtual screening. The results of enrichment analysis suggested that the underlying mechanism was mainly focused on the biological processes and pathways associated with immune inflammation, proliferation, and apoptosis. Notably, the key pathway was considered as the PI3K-AKT signaling pathway.

Conclusion

In summary, the present study elucidates that SP may suppress inflammation and proliferation and promote apoptosis through the PI3K-AKT pathway, which makes SP a potential treatment against TAO. And this study offers new reference points for future experimental research and provides a scientific basis for more widespread clinical application.

Available only for authorised users

Garrity JA, Bahn RS. Pathogenesis of graves Ophthalmopathy. Implications for prediction, prevention, and treatment. Am J Ophthalmol. 2006;142(1):147–153.e142.PubMedPubMedCentral

Perros P, Hegedus L, Bartalena L, Marcocci C, Kahaly GJ, Baldeschi L, et al. Graves' orbitopathy as a rare disease in Europe: a European group on Graves' Orbitopathy (EUGOGO) position statement. Orphanet J Rare Dis. 2017;12(1):72.PubMedPubMedCentral

Lim SL, Lim AK, Mumtaz M, Hussein E, Wan Bebakar WM, Khir AS. Prevalence, risk factors, and clinical features of thyroid-associated ophthalmopathy in multiethnic Malaysian patients with Graves' disease. Thyroid. 2008;18(12):1297–301.PubMed

Abraham-Nordling M, Bystrom K, Torring O, Lantz M, Berg G, Calissendorff J, et al. Incidence of hyperthyroidism in Sweden. Eur J Endocrinol. 2011;165(6):899–905.PubMed

Sahli E, Gunduz K. Thyroid-associated Ophthalmopathy. Turk J Ophthalmol. 2017;47(2):94–105.PubMedPubMedCentral

Shan SJ, Douglas RS. The pathophysiology of thyroid eye disease. J Neuroophthalmol. 2014;34(2):177–85.PubMed

Maheshwari R, Weis E. Thyroid associated orbitopathy. Indian J Ophthalmol. 2012;60(2):87–93.PubMedPubMedCentral

Coulter I, Frewin S, Krassas GE, Perros P. Psychological implications of graves’ orbitopathy. Eur J Endocrinol. 2007;157(2):127–31.PubMed

Park JJ, Sullivan TJ, Mortimer RH, Wagenaar M, Perry-Keene DA. Assessing quality of life in Australian patients with Graves' ophthalmopathy. Br J Ophthalmol. 2004;88(1):75–8.PubMedPubMedCentral

10.

Weng CY, Li ZF, Hu SD, Luo YS, Feng XT, Zhong Q, et al. Evaluation of quality of life in patients with graves orbitopathy and its influencing factors. Zhonghua Nei Ke Za Zhi. 2019;58(8):577–83.PubMed

11.

Wickwar S, McBain HB, Ezra DG, Hirani SP, Rose GE, Newman SP. What are the psychosocial outcomes of treatment for thyroid eye disease? A systematic review. Thyroid. 2014;24(9):1407–18.PubMed

12.

Genere N, Stan MN. Current and emerging treatment strategies for graves’ Orbitopathy. Drugs. 2019;79(2):109–24.PubMed

13.

Perros P, Crombie AL, Kendall-Taylor P. Natural history of thyroid associated ophthalmopathy. Clin Endocrinol (Oxf). 1995;42(1):45–50.

14.

Bartalena L, Krassas GE, Wiersinga W, Marcocci C, Salvi M, Daumerie C, et al. Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves' orbitopathy. J Clin Endocrinol Metab. 2012;97(12):4454–63.PubMed

15.

Godfrey KJ, Kazim M. Radiotherapy for active thyroid eye disease. Ophthal Plast Recons. 2018;34(4S Suppl 1):S98–S104.

16.

Smith TJ, Hegedus L. Graves' disease. N Engl J Med. 2016;375(16):1552–65.PubMed

17.

Guo Q, Chen Y. Textual research on original plant and dietotherapy history of Prunella vulgaris. Zhongguo Zhong Yao Za Zhi. 2011;36(21):3057–62.PubMed

18.

Ryu SY, Oak MH, Yoon SK, Cho DI, Yoo GS, Kim TS, et al. Anti-allergic and anti-inflammatory triterpenes from the herb of Prunella vulgaris. Planta Med. 2000;66(4):358–60.PubMed

19.

Fang Y, Zhang L, Feng J, Lin W, Cai Q, Peng J. Spica Prunellae extract suppresses the growth of human colon carcinoma cells by targeting multiple oncogenes via activating miR-34a. Oncol Rep. 2017;38(3):1895–901.PubMed

20.

Yin DT, Lei M, Xu J, Li H, Wang Y, Liu Z, et al. The Chinese herb Prunella vulgaris promotes apoptosis in human well-differentiated thyroid carcinoma cells via the B-cell lymphoma-2/Bcl-2-associated X protein/caspase-3 signaling pathway. Oncol Lett. 2017;14(2):1309–14.PubMedPubMedCentral

21.

Sun HX, Qin F, Pan YJ. In vitro and in vivo immunosuppressive activity of Spica Prunellae ethanol extract on the immune responses in mice. J Ethnopharmacol. 2005;101(1–3):31–6.PubMed

22.

Li F, Wu Y, Chen L, Hu L, Liu X. Initial treatment combined with Prunella vulgaris reduced prednisolone consumption for patients with subacute thyroiditis. Ann Transl Med. 2019;7(3):45.PubMedPubMedCentral

23.

Yang K, Guo KQ, Wu HY. Clinical effect of Prunellae Oral liquid on goiter with different thyroid function. Chin J integrated Trad Western Med. 2007;27(1):37–9.

24.

Hong J, Zheng S. Study on the medicacation rule of thyroid-associated opthhaimopathy with the help of traditional Cinese medicine inheritance supporting platform. Asia-Pacific Trad Med. 2019;15(4):169–72.

25.

Hopkins AL. Network pharmacology. The next paradigm in drug discovery. Nat Chem Biol. 2008;4(11):682–90.PubMed

26.

Aguayo-Orozco A, Audouze K, Brunak S, Taboureau O. In silico systems pharmacology to assess Drug's therapeutic and toxic effects. Curr Pharm Des. 2016;22(46):6895–902.PubMed

27.

Ru J, Li P, Wang J, Zhou W, Li B, Huang C, et al. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines. J Chem. 2014;6:13.

28.

Liu H, Wang J, Zhou W, Wang Y, Yang L. Systems approaches and polypharmacology for drug discovery from herbal medicines: an example using licorice. J Ethnopharmacol. 2013;146(3):773–93.PubMed

29.

Varma MV, Obach RS, Rotter C, Miller HR, Chang G, Steyn SJ, et al. Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. J Med Chem. 2010;53(3):1098–108.PubMed

30.

Tao W, Xu X, Wang X, Li B, Wang Y, Li Y, et al. Network pharmacology-based prediction of the active ingredients and potential targets of Chinese herbal radix Curcumae formula for application to cardiovascular disease. J Ethnopharmacol. 2013;145(1):1–10.PubMed

31.

Yang H, Zhang W, Huang C, Zhou W, Yao Y, Wang Z, et al. A novel systems pharmacology model for herbal medicine injection: a case using Reduning injection. BMC Complement Altern Med. 2014;14:430.PubMedPubMedCentral

32.

Lee MK, Ahn YM, Lee KR, Jung JH, Jung OS, Hong J. Development of a validated liquid chromatographic method for the quality control of Prunellae Spica: determination of triterpenic acids. Anal Chim Acta. 2009;633(2):271–7.PubMed

33.

Liang J, Zhang L, Yan X. Identification of the major chemical constituents of Prunella Vulgaris L. by HPLC-ESI-MS/MS. Chin Med Modern Distance Educ China. 2013;11(14):153–4.

34.

Tang G. Determination of active ingredients in Chinese medicine prunella vulgaris by high performance liquid chromatography. J North Pharmacy. 2016;13(4):4–5.

35.

Yang J, Hu YJ, Yu BY, Qi J. Integrating qualitative and quantitative characterization of Prunellae Spica by HPLC-QTOF/MS and HPLC-ELSD. Chin J Nat Med. 2016;14(5):391–400.PubMed

36.

Zhai X, Wu X, Xu X, Gao X. Determination of active ingredients in Chinese medicine Prunella Spica by high performance liquid chromatography. World Latest Med Inform. 2019;19(69):118.

37.

Kim S, Chen J, Cheng T, Gindulyte A, He J, He S, et al. PubChem 2019 update: improved access to chemical data. Nucleic Acids Res. 2019;47(D1):D1102–9.PubMed

38.

Gfeller D, Grosdidier A, Wirth M, Daina A, Michielin O, Zoete V. SwissTargetPrediction: a web server for target prediction of bioactive small molecules. Nucleic Acids Res. 2014;42(Web Server issue):W32–8.PubMedPubMedCentral

39.

Szklarczyk D, Santos A, von Mering C, Jensen LJ, Bork P, Kuhn M. STITCH 5: augmenting protein-chemical interaction networks with tissue and affinity data. Nucleic Acids Res. 2016;44(D1):D380–4.PubMed

40.

Chen X, Ji ZL, Chen YZ. TTD. Therapeutic target database. Nucleic Acids Res. 2002;30(1):412–5.PubMedPubMedCentral

41.

Boyadjiev SA, Jabs EW. Online Mendelian inheritance in man (OMIM) as a knowledgebase for human developmental disorders. Clin Genet. 2000;57(4):253–66.PubMed

42.

Grondin CJ, Davis AP, Wiegers TC, Wiegers JA, Mattingly CJ. Accessing an expanded exposure science module at the comparative Toxicogenomics database. Environ Health Perspect. 2018;126(1):014501.PubMedPubMedCentral

43.

Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, Tzur D, et al. DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008;36(Database issue):D901–6.PubMed

44.

Rebhan M, Chalifa-Caspi V, Prilusky J, Lancet D. GeneCards: a novel functional genomics compendium with automated data mining and query reformulation support. Bioinformatics. 1998;14(8):656–64.PubMed

45.

Team RDC. R. a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2011. http://www.R-project.org.

46.

Szklarczyk D, Morris JH, Cook H, Kuhn M, Wyder S, Simonovic M, et al. The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible. Nucleic Acids Res. 2017;45(D1):D362–8.PubMed

47.

Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2008;4(1):44–57.

48.

Shannon P. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498–504.PubMedPubMedCentral

49.

Missiuro PV, Liu K, Zou L, Ross BC, Zhao G, Liu JS, et al. Information flow analysis of interactome networks. PLoS Comput Biol. 2009;5(4):e1000350.PubMedPubMedCentral

50.

Raman K, Damaraju N, Joshi GK. The organisational structure of protein networks: revisiting the centrality-lethality hypothesis. Syst Synth Biol. 2014;8(1):73–81.PubMed

51.

Zhang Y, Bai M, Zhang B, Liu C, Guo Q, Sun Y, et al. Uncovering pharmacological mechanisms of Wu-tou decoction acting on rheumatoid arthritis through systems approaches: drug-target prediction, network analysis and experimental validation. Sci Rep. 2015;5:9463.PubMedPubMedCentral

52.

Liu H, Wang L, Lv M, Pei R, Li P, Pei Z, et al. AlzPlatform: an Alzheimer's disease domain-specific chemogenomics knowledgebase for polypharmacology and target identification research. J Chem Inf Model. 2014;54(4):1050–60.PubMedPubMedCentral

53.

Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, et al. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem. 2009;30(16):2785–91.PubMedPubMedCentral

54.

Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010;31(2):455–61.PubMedPubMedCentral

55.

Belviranli M, Okudan N. Well-Known Antioxidants and Newcomers in Sport Nutrition: Coenzyme Q10, Quercetin, Resveratrol, Pterostilbene, Pycnogenol and Astaxanthin. In: Lamprecht M, ed. Antioxidants in Sport Nutrition. Boca Raton (FL): CRC Press/Taylor & Francis; 2015.

56.

Zhu S, Wang H, Zhang J, Yu C, Liu C, Sun H, et al. Antiasthmatic activity of quercetin glycosides in neonatal asthmatic rats. 3 Biotech. 2019;9(5):189.

57.

Lin JH, Chen SY, Lu CC, Lin JA, Yen GC. Ursolic acid promotes apoptosis, autophagy, and chemosensitivity in gemcitabine-resistant human pancreatic cancer cells. Phytother Res. 2020.

58.

Mukonowenzou NC, Dangarembizi R, Chivandi E, Nkomozepi P, Erlwanger KH. Administration of ursolic acid to new-born pups prevents dietary fructose-induced non-alcoholic fatty liver disease in Sprague Dawley rats. J Dev Orig Health Dis. 2020:1–12.

59.

Zhang N, Liu S, Shi S, Chen Y, Xu F, Wei X, et al. Solubilization and delivery of Ursolic-acid for modulating tumor microenvironment and regulatory T cell activities in cancer immunotherapy. J Control Release. 2020;320:168–78.PubMed

60.

Lim DY, Jeong Y, Tyner AL, Park JH. Induction of cell cycle arrest and apoptosis in HT-29 human colon cancer cells by the dietary compound luteolin. Am J Physiol Gastrointest Liver Physiol. 2007;292(1):G66–75.PubMed

61.

Ou HC, Pandey S, Hung MY, Huang SH, Hsu PT, Day CH, et al. Luteolin: a natural flavonoid enhances the survival of HUVECs against oxidative stress by modulating AMPK/PKC pathway. Am J Chin Med. 2019;47(3):541–57.PubMed

62.

Zhang BC, Li Z, Xu W, Xiang CH, Ma YF. Luteolin alleviates NLRP3 inflammasome activation and directs macrophage polarization in lipopolysaccharide-stimulated RAW264.7 cells. Am J Transl Res. 2018;10(1):265–73.PubMedPubMedCentral

63.

Jia Z, Chen A, Wang C, He M, Xu J, Fu H, et al. Amelioration effects of Kaempferol on immune response following chronic intermittent cold-stress. Res Vet Sci. 2019;125:390–6.PubMed

64.

Li Q, Hu X, Xuan Y, Ying J, Fei Y, Rong J, et al. Kaempferol protects ethanol-induced gastric ulcers in mice via pro-inflammatory cytokines and NO. Acta Biochim Biophys Sin. 2018;50(3):246–53.PubMed

65.

Wu P, Meng X, Zheng H, Zeng Q, Chen T, Wang W, et al. Kaempferol attenuates ROS-induced hemolysis and the molecular mechanism of its induction of apoptosis on bladder cancer. Molecules. 2018;23(10):2592.

66.

Mo JS, Choi D, Han YR, Kim N, Jeong HS. Morin has protective potential against ER stress induced apoptosis in renal proximal tubular HK-2 cells. Biomed Pharmacother. 2019;112:108659.PubMed

67.

Sultana F, Neog MK, Rasool M. Targeted delivery of morin, a dietary bioflavanol encapsulated mannosylated liposomes to the macrophages of adjuvant-induced arthritis rats inhibits inflammatory immune response and osteoclastogenesis. Eur J Pharm Biopharm. 2017;115:229–42.PubMed

68.

Hyun KH, Gil KC, Kim SG, Sy P, Hwang KW. Delphinidin chloride and its hydrolytic metabolite Gallic acid promote differentiation of regulatory T cells and have an anti-inflammatory effect on the allograft model. J Food Sci. 2019;84(4):920–30.PubMed

69.

Kang H-M, Park B-S, Kang H-K, Park H-R, Yu S-B, Kim I-R. Delphinidin induces apoptosis and inhibits epithelial-to-mesenchymal transition via the ERK/p38 MAPK-signaling pathway in human osteosarcoma cell lines. Environ Toxicol. 2018;33(6):640–9.PubMedPubMedCentral

70.

Yoon JS, Lee HJ, Chae MK, Lee SY, Lee EJ. Cigarette smoke extract-induced adipogenesis in Graves' orbital fibroblasts is inhibited by quercetin via reduction in oxidative stress. J Endocrinol. 2013;216(2):145–56.PubMed

71.

Yoon JS, Lee HJ, Choi SH, Chang EJ, Lee SY, Lee EJ. Quercetin inhibits IL-1beta-induced inflammation, hyaluronan production and adipogenesis in orbital fibroblasts from Graves' orbitopathy. PLoS One. 2011;6(10):e26261.PubMedPubMedCentral

72.

Lisi S, Botta R, Lemmi M, Sellari-Franceschini S, Altea MA, Sisti E, et al. Quercetin decreases proliferation of orbital fibroblasts and their release of hyaluronic acid. J Endocrinol Invest. 2011;34(7):521–7.PubMed

73.

Satari A, Amini SA, Raeisi E, Lemoigne Y, Heidarian E. Synergetic impact of combined 5-fluorouracil and Rutin on apoptosis in PC3 cancer cells through the modulation of P53 gene expression. Adv Pharm Bull. 2019;9(3):462–9.PubMedPubMedCentral

74.

Manzoni AG, Passos DF, da Silva JLG, Bernardes VM, Bremm JM, Jantsch MH, et al. Rutin and curcumin reduce inflammation, triglyceride levels and ADA activity in serum and immune cells in a model of hyperlipidemia. Blood Cells Mol Dis. 2019;76:13–21.PubMed

75.

Malleda C, Ahalawat N, Gokara M, Subramanyam R. Molecular dynamics simulation studies of betulinic acid with human serum albumin. J Mol Model. 2012;18(6):2589–97.PubMed

76.

de Castro LL, de Carvalho e Martins Mdo C, Garcez AM, Pacheco JF, Cunha FV, Moita Neto JM, et al. Hypoalbuminemia and oxidative stress in patients on renal hemodialysis program. Nutr Hosp. 2014;30(4):952–9.PubMed

77.

Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB, et al. Cyclooxygenase in biology and disease. FASEB J. 1998;12(12):1063–73.PubMed

78.

Konuk EB, Konuk O, Misirlioglu M, Menevse A, Unal M. Expression of cyclooxygenase-2 in orbital fibroadipose connective tissues of Graves' ophthalmopathy patients. Eur J Endocrinol. 2006;155(5):681–5.PubMed

79.

Vondrichova T, de Capretz A, Parikh H, Frenander C, Asman P, Aberg M, et al. COX-2 and SCD, markers of inflammation and adipogenesis, are related to disease activity in Graves' ophthalmopathy. Thyroid. 2007;17(6):511–7.PubMed

80.

Ishihara K, Hirano T. IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev. 2002;13(4–5):357–68.PubMed

81.

Gillespie EF, Raychaudhuri N, Papageorgiou KI, Atkins SJ, Lu Y, Charara LK, et al. Interleukin-6 production in CD40-engaged fibrocytes in thyroid-associated ophthalmopathy: involvement of Akt and NF-kappaB. Invest Ophthalmol Vis Sci. 2012;53(12):7746–53.PubMedPubMedCentral

82.

Luo LH, Li DM, Wang YL, Wang K, Gao LX, Li S, et al. Tim3/galectin-9 alleviates the inflammation of TAO patients via suppressing Akt/NF-kB signaling pathway. Biochem Biophys Res Commun. 2017;491(4):966–72.PubMed

83.

Kapadia MK, Rubin PA. The emerging use of TNF-alpha inhibitors in orbital inflammatory disease. Int Ophthalmol Clin. 2006;46(2):165–81.PubMed

84.

Douglas RS, Afifiyan NF, Hwang CJ, Chong K, Haider U, Richards P, et al. Increased generation of fibrocytes in thyroid-associated ophthalmopathy. J Clin Endocrinol Metab. 2010;95(1):430–8.PubMed

85.

Li B, Smith TJ. PI3K/AKT pathway mediates induction of IL-1RA by TSH in fibrocytes: modulation by PTEN. J Clin Endocrinol Metab. 2014;99(9):3363–72.PubMedPubMedCentral

86.

Woeller CF, Roztocil E, Hammond C, Feldon SE. TSHR signaling stimulates proliferation through PI3K/Akt and induction of miR-146a and miR-155 in thyroid eye disease orbital fibroblasts. Invest Ophthalmol Vis Sci. 2019;60(13):4336–45.PubMedPubMedCentral

87.

Kumar S, Nadeem S, Stan MN, Coenen M, Bahn RS. A stimulatory TSH receptor antibody enhances adipogenesis via phosphoinositide 3-kinase activation in orbital preadipocytes from patients with Graves' ophthalmopathy. J Mol Endocrinol. 2011;46(3):155–63.PubMedPubMedCentral

88.

Wang X-X, Wang X-X, Jia X-F, Guo T, Xian T-Z, Liu L, et al. Novel role of SF1 in alleviating thyroid-associated ophthalmopathy through the AMPK/mTOR signaling pathway. Gene. 2019;691:132–40.PubMed

89.

Zhu J, Zhang W, Zhang Y, Wang Y, Liu M, Liu Y. Effects of Spica prunellae on caspase-3-associated proliferation and apoptosis in human lung cancer cells in vitro. J Cancer Res Ther. 2018;14(4):760–3.PubMed

90.

Johnson GL. Defining MAPK interactomes. ACS Chem Biol. 2011;6(1):18–20.PubMed

91.

Verma S, Kesh K, Gupta A, Swarnakar S. An overview of matrix metalloproteinase 9 polymorphism and gastric cancer risk. Asian Pac J Cancer Prev. 2015;16(17):7393–400.PubMed

Title: Mechanisms of Spica Prunellae against thyroid-associated Ophthalmopathy based on network pharmacology and molecular docking
Authors: Yuhan Zhang
Xianzhi Li
Congcong Guo
Jianjun Dong
Lin Liao
Publication date: 01-12-2020
Publisher: BioMed Central
Published in: BMC Complementary Medicine and Therapies / Issue 1/2020
Electronic ISSN: 2662-7671
DOI: https://doi.org/10.1186/s12906-020-03022-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Mechanisms of Spica Prunellae against thyroid-associated Ophthalmopathy based on network pharmacology and molecular docking

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2020

Acupuncture techniques for COPD: a systematic review

Antimicrobial effects of mustard oil-containing plants against oral pathogens: an in vitro study

PAMs inhibits monoamine oxidase a activity and reduces glioma tumor growth, a potential adjuvant treatment for glioma

Pharmacokinetic incompatibility of the Huanglian-Gancao herb pair

A survey of ethnomedicinal plants used to treat cancer by traditional medicine practitioners in Zimbabwe

Induction of peroxisome proliferator activated receptor γ (PPARγ) mediated gene expression and inhibition of induced nitric oxide production by Maerua subcordata (Gilg) DeWolf